Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 07 Aug 2025
Adolescents and young adults with cancer who are navigating life between childhood and early adulthood face a unique set of challenges. Despite overall improvements in cancer survival rates, this group has not experienced ...
Read Full NewsThe World Health Organization on Friday urged governments to do more to control the sale of nicotine pouches, warning that the highly addictive products were being...
Across 273 requests for chest CTs for incidental lung findings on neck imaging, only one indolent lung cancer was detected.
The approval of IV atezolizumab and atezolizumab with hyaluronidase-tqjs is the first for bladder cancer since a 2022 withdrawal of accelerated approval of atezolizumab for urothelial carcinoma.
1.
Big Drop in Cervical Cancer Deaths; Publication Hijackers; A Win for CRC Home Tests
2.
Effective for localizing small, non-palpable breast lesions is ultrasound-guided localization with magnetic seeds.
3.
Surgery after EGFR TKI shows promise in prolonging progression-free survival in metastatic NSCLC
4.
CAR-T Warning for Secondary Malignancies: Warranted or Not?
5.
TRK Inhibitor Active in Treatment-Refractory Glioblastoma
1.
Malignant Prolactinoma: Prolactin Surge with Minimal Growth Masks Widespread Metastases
2.
Tremelimumab: A Potential Breakthrough in Cancer Treatment
3.
A Comprehensive Guide To Understanding Plasma Osmolality
4.
The Role of Alanine Aminotransferase in Liver Health and Disease
5.
Unlocking the Power of Neutrophils: Harnessing Their Disease-Fighting Potential
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
The Landscape of First-Line Treatment for Urothelial Carcinoma- The Conclusion
2.
A Panel Discussion on Clinical Trial End Point for Tumor With PPS > 12 months
3.
Updates on Standard V/S High Risk Myeloma Treatment
4.
What Therapy Would Yield the Best Outcomes In Patients with R/R B-cell ALL?
5.
Understanding the causes of anemia in adults beyond nutritional deficiencies
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge